BLM and pancreatic neoplasm: Except for MSH3, the rest of the germline mutant genes in non-BRCA carriers with TNBC were involved in the HRR pathway, including BLM, PALB2, NBN, RAD51C, and RAD51D, with the mutation rate of 9.26% (5/54), which increased the risk of other cancers, such as PLAB2 for pancreatic cancer (53).